Furthermore, some companies, such as Eli Lilly and Pfizer, have now developed FGF21 analogs and demonstrated their therapeutic potential in clinical trials for the treatment of metabolic diseases (BonDurant & Potthoff, 2018). This evidence concerns the gene FGF21 and metabolic disease.